NEW YORK — Chinese diagnostics firm New Horizon Health has gone public on the Hong Kong Stock Exchange, venture capital firm Qiming Venture Partners said on Thursday.
New Horizon, one of Qiming's portfolio companies, focuses on tests for early cancer screening tests and offers two fecal immunochemical tests approved in China: ColoClear for individuals at high-risk for colorectal cancer and Pupu Tube for general colorectal cancer screening.